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BRD4 belongs to the bromodomain and extratermi-
nal (BET) family of chromatin reader proteins that
bind acetylated histones and regulate gene expres-
sion. Pharmacological inhibition of BRD4 by BET
inhibitors (BETi) has indicated antitumor activity
against multiple cancer types. We show that
BRD4 is essential for the repair of DNA double-strand
breaks (DSBs) and mediates the formation of
oncogenic gene rearrangements by engaging the
non-homologous end joining (NHEJ) pathway.Mech-
anistically, genome-wide DNA breaks are associated
with enhanced acetylation of histone H4, leading to
BRD4 recruitment, and stable establishment of the
DNA repair complex. In support of this, we also
show that, in clinical tumor samples, BRD4 protein
levels are negatively associated with outcome after
prostate cancer (PCa) radiation therapy. Thus, in
addition to regulating gene expression, BRD4 is
also a central player in the repair of DNA DSBs,
with significant implications for cancer therapy.
INTRODUCTION
Perturbations in the repair of DNA double-strand breaks (DSBs)
contribute to the development of multiple cancers through the
formation of oncogenic genomic rearrangements and other
DNA lesions (Fro¨hling and Do¨hner, 2008; Mani and Chinnaiyan,
2010). For example, genomic rearrangements involving erythro-796 Cell Reports 22, 796–808, January 16, 2018 ª 2018 The Authors
This is an open access article under the CC BY-NC-ND license (http://blast transformation-specific (ETS) transcription factor family
genes are considered driver events in prostate cancer (PCa)
development. These rearrangements typically involve the fusion
of androgen-regulated transcriptionally active genes with the
ETS genes, resulting in the overexpression of the latter (Tomlins
et al., 2005). Themost prevalent ETS gene rearrangement, which
is observed in >50% of PCas, involves the fusion of androgen
receptor (AR) target gene, TMPRSS2, with the ERG proto-onco-
gene, resulting in the formation of the TMPRSS2-ERG gene
fusion. A combination of three-dimensional spatial proximity of
the gene fusion partner loci and DNA breaks has been shown
to promote the formation of gene fusions (Haffner et al., 2010;
Lin et al., 2009; Mani et al., 2009, 2016). However, the DNA repair
pathways and chromatin modifications underlying the formation
of genomic rearrangements are far from clear.
BRD4 belongs to the bromodomain and extraterminal (BET)
family of reader proteins that translate signal-dependent chro-
matin alterations into gene expression readouts (Wu and Chiang,
2007). Preclinical studies have highlighted the impact of BET in-
hibitors (BETi) as potent anticancer agents. This has led to the
development of clinical trials involving BET inhibitors as single
agents or in combination with existing treatment options in mul-
tiple human cancers. Given the role of BRD4 in regulating histone
acetylation-driven gene expression, it is generally believed that
the anticancer effects of BETi is due to downregulation of
BRD4 target genes like MYC, or by blunting the transcriptional
output mediated by the androgen receptor (AR). However,
downregulation of individual genes or gene signatures is insuffi-
cient to explain the magnitude of phenotypic effects conferred
by BETi. For example, ectopic overexpression of MYC only
partially rescues BETi-mediated inhibition of PCa cell growth;
BETi being more effective than the AR inhibitor enzalutamide in.
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Regulation of DNA Repair Genes
and NHEJ DNA Repair by BET Inhibitors
(A) Histogram representation of beta values indi-
cating gene expression (from RNA-seq experiment)
upon treatment of LNCaP cells with I-BET151 for
8 hr. Red colored bars represent 10 NHEJ genes.
(B) Heatmap representation of the expression of
DNA repair genes (from RNA-seq experiment) upon
treatment of LNCaP cells with the indicated doses
of I-BET151.
(C) Gene set enrichment analysis (GSEA) of BRD4
expression level from castration-resistant PCa
(CRPC) specimens (n = 122) against the 10 NHEJ
DNA repair genes.
(D) Schematic of the NHEJ DNA repair assay.
(E) Representative flow cytometry profiles to
describe the effects JQ1 on the repair of I-SceI-
induced DNA DSBs by the NHEJ pathway.
(F and G) Quantitative analysis of the effects of JQ1
(F) or siRNA against BRD4 (G) on the repair of
I-SceI-induced DNA DSBs by the NHEJ pathway
(*p < 0.05; **p < 0.01; ***p < 0.001 by two-tailed
Student’s t test; error bars, SD of 3 technical
replicates).
(H) BRD4 RNA expression in normal prostate, ERG
fusion positive and SPOP mutant primary prostate
adenocarcinoma samples from TCGA dataset.blocking castration-resistant PCa (CRPC) development in vivo
(Asangani et al., 2014; Wyce et al., 2013). Thus, BETi mediate
their phenotypic effects by blocking additional pathways that
are essential for cancer cell survival. As histone acetylation is
associated both with gene expression regulation and DNA repair
(Lee and Workman, 2007), we explored the role of BRD4 in the
repair of DNA DSBs. In this paper, we present experimental
and clinical data to suggest that BRD4 is a key mediator of
NHEJDNA repair pathway, promotes the formation of oncogenic
gene fusions, and, importantly, is associated with PCa radiation
therapy outcomes.
RESULTS
BET Inhibition Regulates the Expression of DNA Repair
Genes
We reasoned that histone acetylation-dependent, BRD4-medi-
ated transcriptional regulation and DNA repair activity may beCellcomplementary. Thus, we conducted
RNA sequencing (RNA-seq) experiments
to study the gene expression changes in
LNCaP cells upon BET inhibition with
I-BET151. The downregulation of MYC
expression in I-BET151-treated LNCaP
cells served as a positive control for the
experimental setup (Figure S1A). The
expression levels of 7 out of 10 NHEJ
pathway genes decreased upon treatment
with I-BET151 (Figures 1A and 1B). The re-
sults of gene set enrichment analysis tests
indicated that treatment with I-BET151regulated the NHEJ pathway with near significance (p = 0.08).
Consistent with the I-BET151 data, we observed that treatment
with JQ1 (Filippakopoulos et al., 2010), the most commonly
used BETi, also downregulated the expression of NHEJ DNA
repair genes in two PCa cell lines (Figure S1B). We observed
that small interfering RNA (siRNA)-based knockdown of BRD4,
BRD2, or BRD3 resulted in the downregulation of many NHEJ
DNA repair genes (Figure S2A). Simultaneous knockdown of all
the three BET proteins was associated with maximal downregu-
lation of NHEJ DNA repair genes in LNCaP and 22Rv1 cells,
suggestive of functional redundancy among BET proteins. In
addition, overexpression of BRD4 in LNCaP cells resulted in up-
regulation of the NHEJ DNA repair genes in a dose-dependent
manner (Figure S2B). Given the observation that AR upregulates
DNA repair genes (Goodwin et al., 2013; Polkinghorn et al.,
2013), and BRD4 is essential for AR-dependent gene expression
(Asangani et al., 2014), it is not surprising that BETi blocks the
expression of DNA repair genes in prostate cells. To exploreReports 22, 796–808, January 16, 2018 797
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the clinical significance of this experimental approach, we con-
ducted gene set enrichment analysis (GSEA) by mining BRD4
expression from RNA-seq datasets representing 122 CRPC pa-
tients from the SU2C cohort (Robinson et al., 2015). Remarkably,
the 10 NHEJ pathway genes were significantly enriched and
positively associated with BRD4 expression in clinical speci-
mens (Figure 1C). Thus, we conclude that BRD4 regulates the
expression of NHEJ DNA repair genes both in cell-based exper-
imental models and CRPC clinical specimens.
The Role of BRD4 in NHEJ DNA Repair Pathway
As NHEJ DNA repair is the primary mediator of oncogenic
genomic rearrangements, we explored the role of BRD4
in this pathway. We employed an engineered HEK293 cell
line that expresses red fluorescent protein (RFP) only upon
the repair of I-SceI endonuclease-induced DSBs by NHEJ
(Mukherjee et al., 2012). The parental cells are GFP positive
and RFP negative; transfection with an I-SceI expressing
plasmid results in the formation of DSBs flanking the GFP
gene (Figure 1D). The percentage of RFP positive cells
following I-SceI transfection directly correlates with NHEJ ac-
tivity in this assay. Treatment with JQ1 reduced the percentage
of RFP positive cells in a dose-dependent manner, demon-
strating inhibition of NHEJ DNA repair (Figures 1E and 1F).
Consistent with this observation, BRD4 knockdown using
siRNA also resulted in impaired NHEJ DNA repair (Figures 1G
and S3A). These results indicated that BRD4 has an essential
role in the general repair of DNA DSBs by NHEJ.
Next, we queried BRD4 transcript expression in The Cancer
Genome Atlas (TCGA) primary PCa dataset (Cancer Genome
Atlas Research Network, 2015). BRD4 expression was not signif-
icantly altered in PCa specimens when compared to normal
prostate (Figure S3B). As ERG fusion positive and SPOP muta-
tion positive specimens represent the two major, but mutually
exclusive molecular subtypes of PCa, we reasoned that BRD4
may be differentially expressed in these molecular subtypes.
BRD4 expression was significantly elevated in ERG fusion posi-
tive PCa specimens in comparison to either normal prostate or
SPOP-mutated PCa specimens (Figure 1H); no significantFigure 2. BRD4 Promotes TMPRSS2-ERG Genomic Rearrangements
(A) Schematic representation of the CRISPR-Cas9 assay to engineer TMPRSS2-E
introns of TMPRSS2 and ERG genes are indicated by red arrows.
(B) A TaqMan qRT-PCR assay to detect TMPRSS2-ERG fusion RNA transcripts. T
represent sgRNAs that target the ERG locus.
(C) A TaqMan quantitative qPCR assay to detect the specific TMPRSS2-ERG fu
sgRNAs.
(D) Sequence analysis of TMPRSS2-ERG fusion genomic DNA junction in LNC
structures for TMPRSS2 and ERG are shown using the GenBank reference sequ
(E) Sequence analysis of TMPRSS2-ERG fusion transcript junction in LNCaP cel
(F and G) TaqMan qPCR assay to detect the specific TMPRSS2-ERG fusion genom
in LNCaP cells treated with siRNA against BRD4, in combination with sgRNAs targ
four-individual siRNAs against BRD4 (*p < 0.001 by two-tailed Student’s t test; e
(H and I) TaqMan qPCR assay to detect the specific TMPRSS2-ERG fusion genom
LNCaP cells treated with various doses of JQ1, in combination with sgRNAs targ
(J) Quantitative analysis of the effects of siRNA against BRD2 on the repair of
Student’s t test; error bars, SD of 3 technical replicates).
(K and L) TaqMan qPCR assay to detect the specific TMPRSS2-ERG fusion genom
in LNCaP cells treated with siRNA against BRD2, in combination with sgRNAs targ
four individual siRNAs against BRD2 (*p < 0.001 by two-tailed Student’s t test; echanges in BRD4 expression was noted upon comparison of
normal prostate and SPOP-mutated PCa. Thus, we conducted
the next set of experiments to define the role of BRD4 in the for-
mation of ERG gene rearrangements.
The Role of BRD4 in the Formation of Oncogenic
TMPRSS2-ERG Gene Fusions
We employed CRISPR-Cas9 technology to induce de novo
TMPRSS2-ERG gene fusions in androgen-responsive LNCaP
cells, which lack these gene fusions. We hypothesized that co-
transfection of single-guide RNAs (sgRNAs) targeting intron 1 of
TMPRSS2 and intron 3 of ERG would result in the simultaneous
formation of Cas9-mediated DSBs in these two genes. While
the cellular DNA repair machinery will fix most of these DNA
DSBs, a subset of these breaks will inter-ligate to form
TMPRSS2-ERG gene fusions (Figure 2A). We designed three
different sgRNAs per gene and tested all the nine combinations
for their ability to induce TMPRSS2-ERG gene fusions using
TaqMan qRT-PCR assays. Seven of these nine sgRNA combina-
tions induced the robust formation of TMPRSS2-ERG gene fusion
RNA transcripts (Figure 2B). The T3 and E2 sgRNAs targeting
TMPRSS2 and ERG, respectively, were themost effective combi-
nation in terms of gene fusion formation. Although all sgRNA com-
binations produced identical TMPRSS2-ERG fusion RNA tran-
script junctions, the genomic DNA junctions were unique for
each sgRNA combination, as the DSBs are generated in different
locations within the same introns.We developed a TaqMan qPCR
assay to detect the predicted T3 and E2 sgRNA-induced
TMPRSS2-ERG fusion genomic DNA junction. This assay was
specific for the detection of fusions generated by the T3 and E2
sgRNA combination (Figure 2C). The CRISPR-Cas 9-induced
genomic and transcript junctions were characterized by gel-
based PCR, cloning, and sequencing (Figures 2D, 2E, S3C, and
S3D). Importantly, the CRISPR-Cas9 system resulted in the for-
mation of detectable levels of ERG protein in LNCaP cells. More-
over, consistent with the TMPRSS2-ERG fusion transcript data,
the T3 and E2 sgRNA combination was associated with the
maximal induction of ERG protein levels (Figure S3E). Thus, the
CRISPR-Cas9 method allowed rapid, robust, and inducibleRG genomic rearrangements. The single-guide RNA (sgRNA) target sites in the
1, T2, and T3 represent sgRNAs that target the TMPRSS2 locus; E1, E2, and E3
sion genomic DNA junction induced by combination treatment with T3 and E2
aP cells obtained by combination treatment with T3 and E2 sgRNAs. Gene
ences NM_005656 and NM_004449, respectively.
ls obtained by combination treatment with T3 and E2 sgRNAs.
ic DNA junction (F) or TaqMan-qRT-PCR assay for RNA transcript junction (G)
eting TMPRSS2 and ERG genes. siBRD4 (pool) represents combination of the
rror bars, SD of 3 technical replicates).
ic DNA junction (H) or TaqMan-qRT-PCR assay for RNA transcript junction (I) in
eting TMPRSS2 and ERG genes.
I-SceI-induced DNA DSBs by the NHEJ pathway (***p < 0.001 by two-tailed
ic DNA junction (K) or TaqMan-qRT-PCR assay for RNA transcript junction (L)
eting TMPRSS2 and ERG genes. siBRD2 (pool) represents combination of the
rror bars, SD of 3 technical replicates).
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formation of oncogenic gene fusions. We next employed the T3
and E2 sgRNA combination to identify mediators of gene fusion
formation in subsequent experiments.
As the non-homologous end joining (NHEJ) DNA repair
pathway is implicated in the formation of chromosomal translo-
cations (Roukos and Misteli, 2014), we explored the role of this
pathway in the formation of gene fusions. We studied the effect
of knockdown of key NHEJ components such as PRKDC, PAXX,
Artemis, KU70, KU80, XRCC4, LIG4, NHEJ1, XPF, 53BP1, and
WRN in CRISPR-Cas9-mediated TMPRSS2-ERG gene fusion
formation. As hypothesized, knockdown of individual NHEJ
components blocked CRSPR-Cas9-mediated TMPRSS2-ERG
gene fusion formation both in terms of fusion genomic DNA
and fusion RNA transcript (Figures S3F, S3G, and S4A). Consis-
tent with this observation, treatment with NU7026, a PRKDC in-
hibitor, blocked the formation of TMPRSS2-ERG gene fusions in
a dose-dependent manner (Figures S4D and S4E). By recapitu-
lating the role of NHEJ components, we validated the potential of
our CRISPR-Cas9 assay to identify mediators of genomic rear-
rangements. This set the stage to discover novel regulators of
genomic rearrangements.
We next tested the role of BRD4 in CRISPR-Cas9-mediated
TMPRSS2-ERG gene fusion formation. BRD4 knockdown using
four different siRNAs either individually or pooled, resulted in a
significant block in TMPRSS2-ERG gene fusion formation,
both in terms of fusion genomic DNA and fusion RNA transcript
(Figures 2F, 2G, S4B, and S4C). Treatment with the BETi, JQ1,
also blocked the formation of TMPRSS2-ERG gene fusions in
a dose-dependent manner (Figures 2H and 2I). Thus, BRD4 is
necessary for the formation of oncogenic TMPRSS2-ERG gene
fusions, and possibly other genomic rearrangements as well.
BRD2 Promotes NHEJ DNA Repair and the Formation
of Oncogenic TMPRSS2-ERG Gene Fusions
Analysis of RNA-seq data from the SU2C cohort revealed
that the expression of BRD4, BRD2, and BRD3 are correlated
(Figure S5A). The endogenous expression of individual BET pro-
teins was confirmed by immunoblot analysis in LNCaP cells
(Figure S5B). BRD2 knockdown using siRNA also resulted in
impaired NHEJ DNA repair (Figures 2J and S5C). These results
indicated that BRD2 also promotes the repair of DNA DSBs by
NHEJ. We tested the role of BRD2 in CRISPR-Cas9-mediated
TMPRSS2-ERG gene fusion formation. BRD2 knockdown using
multiple siRNAs either individually or pooled, resulted in a signif-
icant block in TMPRSS2-ERG gene fusion formation, both in
terms of fusion genomic DNA and fusion RNA transcript (Figures
2K, 2L, and S5D). We conclude that BRD2 is also necessary for
CRISPR-Cas9-induced TMPRSS2-ERG gene fusion formation.
Ionizing Radiation Induced DNA Damage-Dependent
Genome-wide Acetylation of Histone H4
As acetylated histone H4 is the classic recognition target for
BRD4 (Chiang, 2009), we hypothesized a DNA damage-induced,
acetylation-dependent mechanism for recruitment of BRD4
to damaged chromosomes. Chromatin immunoprecipitation
sequencing (ChIP-seq) experiments in LNCaP cells revealed
that ionizing radiation (IR) treatment induced a significant,
genome-wide increase in acetylation of histone H4 (Figures800 Cell Reports 22, 796–808, January 16, 20183A–3C). Although we observed an increase in histone H4 acety-
lation in transcription start sites (TSSs) (Figure 3D), mainly at +1
nucleosome where BRD4 typically binds, this did not fully ac-
count for the substantial increase in genome-wide histone H4
acetylation upon IR treatment (cf. Figures 3C and 3D). As the pri-
mary effect of IR on chromatin is DNA damage, we reasoned that
the enhanced histone H4 acetylation is likely to be directed to
sites of DNA damage. DNase I hypersensitivity sites (DHSs) are
hotspots for breaks; we have previously reported the involve-
ment of DHSs in the formation of oxidative stress-induced de
novo genomic rearrangements (Mani et al., 2016). Interestingly,
we observed a significant increase in histone H4 acetylation in
DHSs upon IR treatment (Figure 3E). The signature bi-modal
peak is suggestive of nucleosome loss at the center of DHSs,
which is associated with increased susceptibility to DNA breaks.
The prostate-specific transcriptionally active TMPRSS2 locus
has high levels of acetyl histone H4 at the TSS (Figure 3F, top).
The first intron of TMPRSS2, a hotspot for DNA breaks, is the
most frequently rearranged intron in PCa genomes as it fuses
multiple ETS family genes, including ERG, to form the ETS
gene fusions. We observed DHSs in the first intron of TMPRSS2.
IR treatment induced significant acetylation of histone H4 in the
first intron of TMPRSS2. These results suggest that DNA dam-
age is associated with enhanced histone acetylation.
Homozygous deletions spanning thePTEN locus are observed
in about 15% of primary PCas (Barbieri et al., 2012; Cancer
Genome Atlas Research Network, 2015). The TSS of PTEN is en-
riched for the acetyl histone H4 mark (Figure 3F, bottom). We
observed two IR-induced histone H4 acetylation sites near the
50 and 30 ends of the PTEN genes. One of these two acetylated
sites is also a DHS, suggesting that the induced acetylation sites
are hotspots for DNA breaks. We speculate that mis-repair of
simultaneous DSBs at these induced acetylation sites could
contribute to PTEN loss in PCa.
DNA Damage-Dependent Recruitment of BRD4 to
Chromatin Results in Stable Establishment of the DNA
Repair Complex
We conducted IR treatment and cell fractionation assays to
further probe the role of acetylated histone H4 and BRD4 in
the repair of DNA DSBs. Treatment of LNCaP cells with IR re-
sulted in enhanced acetylation of histone H4 and increased
recruitment of BRD4 to the chromatin fraction (Figure 4A, top).
Co-immunoprecipitation experiments indicated that histone H4
acetylation mediated the recruitment of BRD4 to chromatin
upon DNA damage (Figure 4A, bottom). g-H2AX, representing
phosphorylated histone H2AX (Ser139) was used as a positive
control for DNA damage; H2AX and b-tubulin were employed
as positive controls for chromatin and cytosolic fractions,
respectively. Treatment with the BETi, JQ1, blocked the recruit-
ment of BRD4 to the chromatin upon IR-induced DNA damage
(Figure 4B).
Next, we hypothesized that, upon DNA damage, BRD4 inter-
acts with additional DNA repair proteins, leading to their recruit-
ment/stabilization, and the establishment of functional DNA
repair complexes. BRD4 co-immunoprecipitated with several
other proteins associated with DNA repair including 53BP1,
KU80, KU70, and H2AX (Figure 4C). Acetylated histone H4, the
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Figure 3. Ionizing Radiation Induces Acetylation of Histone H4 in the Chromatin
(A) Heatmap representation of ChIP-seq signals ±4 kb around Acetyl histone H4 peaks in LNCaP cells treated with or without 5 Gy IR. Samples were processed
4 hr post-treatment. The heatmaps are paired and sorted by the 0-Gy treatment.
(B) Venn diagram representing acetyl histone H4 peaks in untreated or 5-Gy IR-treated LNCaP cells.
(C–E) Average coverage plots showing enrichment of Acetyl histone H4 genome-wide (C), at transcription start sites (TSS) (D) and DNase I hypersensitivity sites
(DHSs) (E).
(F) Genome browser representation of Acetyl histone H4 peaks in TMPRSS2 and PTEN genes. Black triangles represent common peaks and red triangles
represent IR-induced peaks.primary recognition target for BRD4 was included as a positive
control in these experiments; immunoglobulin G (IgG) was the
negative control. The interaction of BRD4 with DNA repair pro-
teins was further enhanced upon IR treatment. Thus, functional
interactions between BRD4 and DNA repair proteins represent
a potential mechanism for the role of BRD4 in NHEJ DNA repair.
We were intrigued by the interaction between the reader
proteins BRD4 and 53BP1, which was significantly enhanced
upon IR treatment. 53BP1 is a mediator of the DNA damage
checkpoint (DiTullio et al., 2002; Fernandez-Capetillo et al.,
2002; Wang et al., 2002), and, importantly, IR-induced 53BP1
foci formation is a hallmark of DNA damage response (DDR)signaling (Schultz et al., 2000). The BRD4-53BP1 interaction
was confirmed by reverse co-immunoprecipitation experiments
using both BRD4 and 53BP1 antibodies (Figure S6A). The results
of proximity ligation assay (PLA) provided additional confirma-
tion that IR treatment enhances the interaction between BRD4
and 53BP1 (Figures S6B and S6C).
We conducted the next set of experiments to explore the func-
tional consequence of the interaction between BRD4 and
53BP1. Treatment with the BETi, JQ1, blocked the recruitment
of 53BP1 to chromatin upon IR-induced DNA damage in LNCaP
cells (Figure 4D). Similar results were obtainedwith siRNA-based
BRD4 knockdown experiments (Figure S7A). Knockdown ofCell Reports 22, 796–808, January 16, 2018 801
AC
E F
D
B Figure 4. BRD4 Is Recruited to the Chro-
matin upon DNA Damage and Functionally
Interacts with DNA Repair Proteins
(A) Histone H4 acetylation and BRD4 recruitment
to the chromatin upon ionizing radiation (IR)-
induced DNA damage (20 Gy) in LNCaP cells (top).
g-H2AX is the positive control for IR treatment;
H2AX serves as positive control for the chromatin
fraction and negative control for cytosolic fraction;
b-tubulin serves as positive control for cytosolic
fraction and negative control for chromatin frac-
tion. BRD4 was immunoprecipitated from the
same lysates and analyzed by immunoblot using
anti-acetyl histone H4 antibody (bottom).
(B) The role of JQ1 in recruitment of BRD4 to the
chromatin upon IR-induced DNA damage (20 Gy)
in LNCaP cells.
(C) Co-immunoprecipitation (Co-IP) experiments
with nuclear extracts from untreated or IR-treated
LNCaP cells (20 Gy). 1 hr post-IR treatment, the
immunoprecipitation (IP) was performed using
anti-BRD4 antibody and analyzed by immunoblot
with the indicated antibodies.
(D) The role of JQ1 (10 mM) in the recruitment of
BRD4, 53BP1, Artemis, and Ku80 to the chromatin
upon IR-induced DNA damage (20 Gy) in LNCaP
cells.
(E and F) The role of dBET1 (1 mM) in the recruit-
ment of BRD4 and DNA repair proteins to
the chromatin upon IR-induced DNA damage in
LNCaP (E) and 22Rv1 cells (F).53BP1 did not block the recruitment of BRD4 to chromatin upon
IR-induced DNA damage, suggesting BRD4 functions upstream
of 53BP1 in the cascade of DNA repair events (Figure S7B).
Given that both BRD4 and 53BP1 are reader proteins, we pro-
pose that BRD4 functions upstream in hierarchy and thus serves
as a chromatin bookmark to guide the 53BP1 reader. Moreover,
treatment with JQ1 blocked the recruitment of additional DNA
repair proteins like Artemis and KU80 to the chromatin upon
IR-induced DNA damage (Figure 4D). IR treatment did not affect
the steady-steady expression of BET proteins or DNA repair pro-
teins in LNCaP and 22Rv1 cells (Figure S7C). These results indi-
cate that BRD4 is critical for stable formation of DNA repair
complexes.
We extended our studies to dBET1, a next-generation
BETi, synthesized by the conjugation of JQ1 with pthalimide802 Cell Reports 22, 796–808, January 16, 2018moiety (Winter et al., 2015). dBET1 in-
duces selective degradation of BET pro-
teins. We observed that treatment with
dBET1 blocked the IR-induced recruit-
ment of BRD4, 53BP1, Artemis, KU80
and XRCC4 to the chromatin in two
different cell line models—LNCaP and
22Rv1 (Figures 4E and 4F). Overall,
therefore these results indicate that
BRD4 participates in NHEJ DNA repair
by (1) regulating the expression of
NHEJ DNA repair genes, and (2) physi-
cally and functionally interacting withNHEJ DNA repair proteins, thereby contributing to the forma-
tion of stable DNA repair complexes, and resulting in efficient
DNA repair.
Loss of BRD4 Function Enhances IR-Induced g-H2AX
Foci Formation
We next evaluated the effect of JQ1 and siRNA-based knock-
down of BRD4 on IR-induced g-H2AX foci formation in LNCaP
cells. Treatment with JQ1 enhanced IR-induced g-H2AX foci
formation (Figures 5A and 5B). Consistent with this observa-
tion, BRD4 knockdown significantly enhanced IR-induced
g-H2AX foci formation (Figures 5C and 5D). Treatment with
JQ1 or BRD4 knockdown in the absence of IR did not result
in g-H2AX foci formation. Interestingly, a high-throughput
RNAi study has also identified BRD4 as a significant effector
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Figure 5. Loss of BRD4 Function Promotes
H2AX Phosphorylation after IR Treatment
(A–D) The effect of BRD4 knockdown (A and B) or
incubation with 1 mM JQ1 (C and D) in the phos-
phorylation of histone H2A.X (Ser139) upon treat-
ment of LNCaP cells with IR (5 Gy). The cells were
analyzed at 30 and 120 min post-IR treatment; scale
bar, 10 mm. The number of g-H2AX foci, above
threshold intensity per nucleus (n = 165) was quan-
tified using the ImageJ software (***p < 0.0001 by
two-tailed Mann-Whitney U test).of IR-induced g-H2AX foci formation (Floyd et al., 2013). Over-
all, these results indicate that absence of BRD4 results in
defective repair of IR-induced DNA breaks.
BETi Synergizes with Enzalutamide to Enhance
IR-Induced DNA Damage
We conducted comet assays to study the role of BRD4 in the
restoration of genome integrity upon IR-induced DNA damage.
IR treatment resulted in a dose-dependent increase in comet
tail moment in LNCaP cells, indicating an increase in the pro-
portion of unrepaired DNA breaks. BRD4 knockdown signifi-
cantly enhanced IR-induced comet tail moment (Figures 6A
and 6B). BRD4 knockdown in the absence of IR treatment
did not increase comet tail moment, indicating that BRD4
loss does not contribute to the formation of DNA breaks per
se, rather it modulates the downstream DNA repair events.
Furthermore, these findings with BRD4 knockdown were reca-
pitulated with pharmacological BETi by JQ1. The effects with
JQ1 were more pronounced especially at low doses of IR
treatment (Figure 6C and 6D). Since JQ1 targets multiple mem-
bers of the BET family proteins, when compared to the siRNA,
which only targets BRD4, it is reasonable to observe enhanced
effects with JQ1.
We also conducted rescue experiments by overexpressing
FLAG-tagged BRD4 in LNCaP cells. Treatment of LNCaP
cells with IR resulted in enhanced recruitment of ectopicallyCelexpressed FLAG-BRD4 to the chromatin
fraction (Figure S7D). Remarkably, BRD4
overexpression led to a reduction in
comet tail moment upon IR treatment,
indicating a decrease in the proportion
of unrepaired DNA breaks (Figure S7E).
The results of these experiments clearly
demonstrate an important role for BRD4
in the repair of DNA breaks.
Drugs targeting DNA repair including
poly-(ADP)-ribose polymerase (PARP) in-
hibitors have been associated with anti-
tumor activity in PCa subsets (Mateo
et al., 2015). We next explored the utility
of targeting DNA repair with BETi. The
combination of androgen deprivation
therapy (ADT) and radiation therapy (RT)
is commonly used in the treatment of
PCa. In patients with clinically lymph-node-positive PCa, compared with ADT alone, ADT+RT was
associated with a decreased risk of 5-year all cause mortality
(Lin et al., 2015). Likewise, compared to RT alone, RT + short-
term ADT was associated with decreased PCa-specific
mortality and increased overall survival (Jones et al., 2011).
Mechanistically, ADT blocks AR-mediated DNA repair and
thus improves the efficacy of RT (Goodwin et al., 2013; Pol-
kinghorn et al., 2013; Spratt et al., 2015). Thus, we tested
the effect of JQ1 and the AR antagonist, enzalutamide (as
single agents or in combination) in IR-induced DNA damage
(Figure 6E). Similar to our earlier result, JQ1 significantly
increased IR-induced comet tail moment in LNCaP cells that
endogenously express wild-type AR. Treatment of LNCaP
cells with enzalutamide showed a small, but statistically
non-significant increase of IR-induced comet tail moment.
The combination of JQ1 and enzalutamide synergistically
increased IR-induced comet tail moment in LNCaP cells (Fig-
ure 6E, left). We conducted this experiment in 22Rv1 cells that
endogenously express both wild-type AR and a splice variant
of AR that does not bind enzalutamide. Treatment with JQ1,
but not enzalutamide, increased IR-induced comet tail
moment in 22Rv1 cells. However, JQ1 did not synergize
with enzalutamide to increase comet tail moment in 22Rv1
cells (Figure 6E, right). These results indicate that BETi can ra-
diosensitize cells expressing AR splice variants that escape
enzalutamide blockade.l Reports 22, 796–808, January 16, 2018 803
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Figure 6. BRD4 Inhibition Synergizes with IR to Promote DNA Damage
(A) Alkaline comet assay of LNCaP cells with non-targeting siRNA or BRD4 siRNA, followed by treatment with the indicated doses of IR. Cells were irradiated 72-hr
post-siRNA treatment, followed by recovery after 30 min.
(B) Quantification of alkaline comet assay Olive tail moment (top) and validation of BRD4 knockdown by immunoblotting (bottom).
(C) Alkaline comet assay of LNCaP cells treated with 1 mM JQ1 for 24 hr, followed by IR treatment, and recovery after 30 min.
(D) Quantification of alkaline comet assay Olive tail moment.
(E) Alkaline comet assay quantification of single-agent or combination treatment of LNCaP (left) and 22Rv1 cells (right) with 1 mM JQ1 and/or 1 mM enzalutamide
for 24 hr followed by IR treatment and recovery after 30 min (**p < 0.01; ***p < 0.001; ****p < 0.0001 by unpaired Student’s t test; error bars, SD of n > 50 cells from
each sample).
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Figure 7. Nuclear BRD4 Expression Corre-
lates with Progression to Castration Resis-
tance PCa
(A) Representative IHC images and HS for BRD4
expression in diagnostic biopsies of prostate
adenocarcinoma.
(B) Median HS and interquartile range for nuclear
BRD4 expression in normal (39 patients), prostatic
intraepithelial neoplasia (PIN; 37 patients), and
adenocarcinoma (28 patients). Patients with
adenocarcinoma were divided by BRD4 low
(HS <100; 11 patients; gray) and BRD4 high
(HS R100; 17 patients; red) for further analysis.
BRD4 expression between groups was not signif-
icantly different using Kruskal-Wallis equality-of-
populations rank test (p = 0.92).
(C and D) Kaplan-Meier curves of time to CRPC
(C) (y axis represents percent hormone-sensitive
PCa [HSPC]) and overall survival (D) from diag-
nosis after radical primary therapy are shown for
low BRD4 (gray) and high BRD4 (red) groups.
Hazard ratios (HRs) with 95% confidence in-
tervals and p values for univariate cox survival
model are shown.Association of Nuclear BRD4 Protein Expression
with the Development of CRPC after RT
To extend our discoveries to the clinical context, we optimized
BRD4 protein immunohistochemistry (IHC) staining in formalin-
fixed, paraffin-embedded (FFPE) PCa sections (Figure 7A).
We next investigated the expression of BRD4 in prostate
carcinogenesis and its association with primary treatment
response. H-scores (HS) were determined by IHC and BRD4
antibody specificity was confirmed using BRD4 siRNA in
LNCaP95 cells (Figure S7F). LNCaP95 is an androgen-inde-
pendent and enzalutamide-resistant cell line derived from the
parental LNCaP cells (Hu et al., 2012). We noticed higher
BRD4 levels in LNCaP95 cells as compared to parental LNCaP
cells (data not shown). We then compared BRD4 expression in
clinical specimens representing normal prostate, prostatic in-
traepithelial neoplasia (PIN) and prostate adenocarcinoma
(Figure 7B). Although variability in BRD4 protein expression
was noted, we did not observe a statistically significant in-
crease in BRD4 levels as patients developed prostate adeno-
carcinoma. This could be perhaps due to differential BRD4
expression in the various molecular subtypes of PCa (e.g.,
ERG fusion positive PCa versus SPOP mutation positive
PCa) as suggested by our analysis of TCGA primary PCa data-
set (Figures 1H and S3B).
As BETi have shown therapeutic activity in multiple pre-clinical
models of cancer, we hypothesized that the inherent levels of
variability in BRD4 levels may influence the outcome of treat-
ments that primarily target genomic integrity (e.g., RT).
Thus, we analyzed the expression of BRD4 in pre-treatment
PCa biopsies of men who underwent primary therapy that
included radical radiotherapy as part of their treatment para-
digm. Higher nuclear BRD4 expression (continuous variable,
per 100 HS) at diagnosis was significantly associated with
shorter time to CRPC development after primary therapy (HR6.7; 95% CI 1.5–31.0; p = 0.01). We divided the patient cohort
by median nuclear BRD4 expression (BRD4 low, HS <100, 11
patients) and BRD4 high, HS R100, 17 patients). Patients in
the high BRD4 group had significantly shorter median time to
the development of CRPC compared to those in the low BRD4
group (2.8 [IQR 1.9–7.7] versus 9.1 [IQR 2.7–10.1] years, HR
3.9 [95%CI 1.4–10.9], p = 0.01; Figure 7C). There were no signif-
icant differences in the baseline characteristics between these
patient groups (Table S1). Finally, we determined whether nu-
clear BRD4 expression was associated with overall survival in
our patient cohort. Consistent with time to CRPC, higher nuclear
BRD4 expression (continuous variable, per 100 HS) at diagnosis
was associated with shorter overall survival (HR 5.5; 95%
CI 1.0–29.7; p = 0.05). Although those patients in the high
BRD4 group had a worse outcome compared to those in the
low BRD4 group, this did not reach statistical significance
(median 8.0 [IQR 5.1–13.5] versus 13.3 [IQR 7.9–13.8] years,
HR 2.1 [0.8–5.5], p = 0.11; Figure 7D). Thus, pre-treatment nu-
clear BRD4 levels are associated with outcome from radical local
RT for PCa.
DISCUSSION
We demonstrate a novel role for BRD4 in the formation of onco-
genic TMPRSS2-ERG fusions via its involvement in the NHEJ
DNA repair pathway. Mechanistically, BRD4 is recruited to
DNA DBSs by its interaction with acetylated histone H4, and
perhaps other acetylated proteins. BRD4 also interacts with
several DNA repair proteins; these interactions are further
enhanced upon IR treatment. Given the role of BRD4 in gene
regulation, it is not surprising that several DNA repair genes are
mis-regulated upon treatment with BETi. We suggest that both
the direct effects of BRD4 in orchestrating the response to IR
or CRISPR-Cas9-induced DNA breaks, and these indirectCell Reports 22, 796–808, January 16, 2018 805
effects by regulating the expression of DNA repair genes, are
likely to be complementary.
We suggest that oncogenic gene fusions mirror many features
of normal cellular processes like antibody gene rearrangements.
BRD4 has been shown to promote class switch recombination
(CSR) in B cells by facilitating the recruitment of 53BP1 to the
switch regions (Stanlie et al., 2014). 53BP1 is essential for CSR
in B lymphocytes (Manis et al., 2004; Ward et al., 2004). We
suggest that DNA damage-induced cooperative interaction
between BRD4 and 53BP1 promotes the formation of
TMPRSS2-ERG gene fusions, presumably by (1) blocking DNA
end resection (Bothmer et al., 2010), (2) promoting/maintaining
synapsis of distal DNA elements (Difilippantonio et al., 2008),
and (3) increasing chromatin mobility (Dimitrova et al., 2008).
53BP1 exhibits structural plasticity and can recognize at least
two different histone marks: the dimethylated histone H4 lysine
20 (H4K20me2) (Botuyan et al., 2006; Sanders et al., 2004), and
the histoneH2Aubiquitinated on Lys 15 (H2AK15ub) (Fradet-Tur-
cotte et al., 2013; Wilson et al., 2016). We speculate that BRD4
may guide 53BP1 to the damaged chromatin and thus serve as
a reader’s reader. Future studies should further refine our under-
standing of the nature, hierarchy, and origins of chromatin codes
that are read by these reader proteins. BRD4 may also stabilize
53BP1 and the other DNA repair proteins at DSBs, leading to
the formation of functional DNA repair complexes.
High-resolution mass spectrometry studies have identified
lysine acetylation sites in several DNA repair proteins, including
KU70 and KU80 (Choudhary et al., 2009). Thus, it is conceivable
that the presence of two bromodomains help BRD4 and possibly
other BET proteins to serve as adaptors to connect chromatin
with acetylated DNA repair proteins. BRD4 may also promote
acetylation-dependent cooperative interactions between DNA
repair proteins leading to the establishment of multi-protein
DNA repair complexes and liquid-liquid phase separation
(Banani et al., 2017; Shin and Brangwynne, 2017). Such a model
has been proposed for transcriptional regulation by super-en-
hancers (Hnisz et al., 2017). As BRD4 is a key component of su-
per-enhancers, our study highlights common themes underlying
the organization/regulation of super-enhancers and DNA repair
complexes, and their vulnerability to BETi.
Our results also indicate that BET inhibition impairs the recruit-
ment of 53BP1, Artemis, KU80, and potentially other DNA repair
proteins to damaged chromatin. We also show that treatment
with JQ1 enhanced IR-induced DNA damage and synergized
with enzalutamide in cells expressing wild-type AR. Mechanisti-
cally, we show that these effects are due to targeting DNA repair.
Since we also show that in clinical PCa samples, BRD4 protein
expression is associated with outcome following radiotherapy,
we now hypothesize that BETi can potentially be employed as
a radiosensitizer in the radical treatment of higher risk localized
PCas, especially in cancers with higher BRD4 expression.
Finally, our study demonstrates a new function for BRD4, a
molecule that is widely implicated in the regulation of gene
expression. Our results reposition BRD4 to the epicenter of
DNA repair. These results are likely to enhance our understand-
ing of cellular response to DNA damage and acquired resistance
to cancer therapies that target DNA integrity, including RT and
DNA-damaging anticancer drugs.806 Cell Reports 22, 796–808, January 16, 2018EXPERIMENTAL PROCEDURES
Cell Culture and Transfection
LNCaP and 22Rv1 cells were obtained from American Type Culture Collection
(ATCC) and cultured in RPMI 1640medium containing 10% fetal bovine serum
(FBS) in a 5%CO2 humidified incubator. HEK293 cells were cultured in Eagle’s
Minimum Essential Medium containing 10% FBS. LNCaP95 cells were ob-
tained from Alan K Meeker and Jun Luo (Johns Hopkins University, Baltimore,
MD, USA). LNCaP95 cells were cultured in phenol red free RPMI 1640medium
supplemented with 10% charcoal-stripped FBS. All cell lines were verified by
genotyping. Plasmid transfection was done using Lipofectamine 3000
(Thermo Fisher Scientific, #L3000015) according to manufacturer’s protocol.
The pFLAG-CMV-BRD4 expression plasmid was a gift from Eric Verdin
(Addgene plasmid #22304) (Bisgrove et al., 2007).
Patients and Tissue Samples
Patients with predominant areas of high-grade PIN and histologically normal
prostate were identified from a population of men treated at UT Southwestern
(UTSW) who underwent radical prostatectomy. UTSW patients provided
written consent allowing the use of discarded surgical samples for research
purposes according to an institutional board-approved protocol (STU-
032011–187). De-identified patient samples were obtained from the UTSW
Tissue Repository.
Patients were identified from a population of men treated at the Royal
Marsden NHS Foundation Trust who received radical treatment for their
PCa and went on to develop castration-resistant PCa (CRPC). Patients
with a diagnosis of prostate adenocarcinoma with sufficient formalin-fixed,
paraffin-embedded archival (diagnostic) tissue for BRD4 IHC were selected.
Archival tissue was obtained from prostate needle biopsy (18), transurethral
resection of the prostate (TURP; 2), or prostatectomy procedures (8). All tis-
sue blocks were freshly sectioned and only considered for IHC analyses if
adequate material was present (R50 tumor cells; reviewed by D.N.R.). All pa-
tients had given written informed consent and were enrolled in institutional
protocols approved by the Royal Marsden NHS Foundation Trust Hospital
(London, UK) ethics review committee (reference no. 04/Q0801/60). A total
of 28 patients had archival tissue sufficient for testing. Demographic and clin-
ical data for each patient were retrospectively collected from the hospital
electronic patient record system.
Tissue Analysis
IHC was performed using the rabbit anti-BRD4 antibody (Abcam;
ab128874). Antigen retrieval was performed on slides in citrate buffer (pH
6.0) using a Menarini automated pressure cooker Menapath Antigen
Access Unit. Anti-BRD4 antibody was diluted at 1:500 in Dako diluent
and tissue was incubated for 1 hr. The reaction was visualized using the
EnVison system. Cases were scored by a pathologist (D.N.R.) blinded to
clinical data using the modified H score (HS) method; a semiquantitative
assessment of staining intensity that reflects antigen concentration. HS
was determined according to the formula: [(% of weak staining) 3 1] +
[(% of moderate staining) 3 2] + [(% of strong staining) 3 3], yielding a
range from 0 to 300. Rabbit IgGs were used as a negative control. Cell pel-
lets from LNCaP95 cells treated with BRD4 siRNA were used to confirm
specificity of the antibody for BRD4.
Statistical Analysis
Time to CRPC was defined as the time from diagnosis (date of diagnostic bi-
opsy unless clinical diagnosis was recorded as >1 month prior to biopsy) to
documented progression (radiological, prostate-specific antigen [PSA], or
change of treatment) on luteinizing hormone-releasing hormone (LHRH) agonist
alone or with anti-androgen if started before/or with LHRH agonist. Overall sur-
vival was defined as time from diagnosis to date of death (21 patients) or last
follow-up/contact (7 patients). Time-to-event end points (overall survival and
time to CRPC)were assessed bymeans of Kaplan-Meiermethods. Association
with Nuclear BRD4 expression level was tested, as a continuous variable and
dichotomized at the median HS of 100, using univariate Cox proportional haz-
ards models. The proportional-hazards assumption was tested with the use of
Schoenfeld residuals. Association between patient characteristics at diagnosis
(age, PSA, Gleason score, and previous treatment) and nuclear BRD4 levels
were tested using two-sample t test, Mann-Whitney U test, chi-square, and
Fisher’s exact test. Differences in nuclear BRD4 HS by cancer progression
stage (normal, PIN, and adenocarcinoma) were assessed using the Kruskal-
Wallis equality-of-populations rank test. All analyses were conducted using
Stata v.13.1 and graphs were generated using GraphPad Prism v.6.
DATA AND SOFTWARE AVAILABILITY
The accession numbers for the ChIP-seq and RNA-seq data are GEO:
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